<DOC>
	<DOCNO>NCT00539513</DOCNO>
	<brief_summary>Obsessive-compulsive disorder ( OCD ) affect 2-3 % population lead great deal suffer . Many patient benefit establish treatment , mainstay cognitive behavioral therapy group antidepressant medication know serotonin reuptake inhibitor . However , 20-30 % patient get minimal benefit establish therapeutic strategy . New avenue treatment urgently need . Existing medication obsessive-compulsive disorder affect neurotransmitter serotonin dopamine ; increase evidence suggest functional disruption different neurotransmitter , glutamate , may contribute case OCD . The researcher therefore interested use medication target glutamate novel treatment option OCD patient benefit establish treatment . One medication drug N-Acetylcysteine , whose glutamatergic antagonistic property may effective reduce glutamatergic hyperactivity think contribute pathophysiology OCD major depressive disorder ( MDD ) . Riluzole , FDA approve amyotrophic lateral sclerosis ( ALS , Lou Gehrig 's disease ) also glutamatergic agent . There evidence riluzole possess anti-depressant , anti-obsessional , anti-anxiety property . The modulation glutamatergic activity promise new approach treatment mood disorder . The researcher therefore recruit patient participate double-blind , placebo-controlled trial N-Acetylcysteine , add whatever OCD medication take .</brief_summary>
	<brief_title>N-Acetylcysteine Augmentation Treatment-Refractory Obsessive-Compulsive Disorder</brief_title>
	<detailed_description>Due limit participation , study close .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Compulsive Personality Disorder</mesh_term>
	<mesh_term>Obsessive-Compulsive Disorder</mesh_term>
	<mesh_term>Compulsive Behavior</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<mesh_term>Serotonin Uptake Inhibitors</mesh_term>
	<criteria>DSMIV diagnosis OCD , confirm SCIDIV ; symptom least 1 year duration moderate severe OCD symptom ( YBOCS &gt; 16 ) document failure adequate trial SSRI agreement engage reliable form birth control ( woman ) primary diagnosis psychotic disorder active substance abuse dependence unstable medical condition prior exposure NAcetylcysteine prior psychosurgery pregnancy , breastfeeding , intent become pregnant study liver function test ( LFTs ) elevate 2x upper limit normal evidence active liver disease seizure disorder active suicidal ideation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>obsessive-compulsive disorder</keyword>
	<keyword>OCD</keyword>
	<keyword>glutamate</keyword>
	<keyword>N-Acetylcysteine</keyword>
	<keyword>augmentation</keyword>
</DOC>